HC Wainwright Has Pessimistic Outlook of MNMD Q3 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – HC Wainwright lowered their Q3 2025 EPS estimates for Mind Medicine (MindMed) in a report issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.36) for the quarter, down from their prior estimate of ($0.35). HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)’s FY2025 earnings at ($1.32) EPS and FY2027 earnings at ($1.31) EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01.

Several other analysts have also issued reports on MNMD. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, May 9th. Evercore ISI assumed coverage on shares of Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They set an “outperform” rating and a $23.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research report on Tuesday, May 13th. Finally, Robert W. Baird reduced their price target on shares of Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Nine investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, Mind Medicine (MindMed) has a consensus rating of “Buy” and an average target price of $25.11.

Mind Medicine (MindMed) Price Performance

Mind Medicine (MindMed) stock opened at $7.30 on Monday. The firm has a market cap of $550.19 million, a PE ratio of -3.23 and a beta of 2.52. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. The stock’s fifty day moving average price is $6.20 and its two-hundred day moving average price is $6.98. Mind Medicine has a one year low of $4.70 and a one year high of $10.44.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Hedge funds have recently added to or reduced their stakes in the business. AWM Investment Company Inc. increased its holdings in Mind Medicine (MindMed) by 39.9% in the fourth quarter. AWM Investment Company Inc. now owns 1,193,162 shares of the company’s stock valued at $8,304,000 after purchasing an additional 340,162 shares during the period. Nuveen LLC acquired a new stake in shares of Mind Medicine (MindMed) in the first quarter valued at about $1,556,000. Marshall Wace LLP increased its stake in shares of Mind Medicine (MindMed) by 9.3% in the fourth quarter. Marshall Wace LLP now owns 2,501,391 shares of the company’s stock valued at $17,410,000 after buying an additional 213,526 shares during the period. Tang Capital Management LLC bought a new position in shares of Mind Medicine (MindMed) during the fourth quarter worth about $1,392,000. Finally, Allostery Investments LP acquired a new stake in Mind Medicine (MindMed) during the 4th quarter valued at approximately $905,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Mind Medicine (MindMed)

In other news, insider Daniel Karlin sold 6,836 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the sale, the insider now directly owns 446,177 shares in the company, valued at approximately $3,007,232.98. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Robert Barrow sold 21,208 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $142,941.92. Following the completion of the transaction, the chief executive officer now directly owns 856,556 shares of the company’s stock, valued at $5,773,187.44. This represents a 2.42% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,391 shares of company stock worth $204,835 over the last quarter. Corporate insiders own 2.45% of the company’s stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.